公司资料
Kiniksa 股价、新闻与催化剂
- 股票代码:
- KNSA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
79.18 USD (+3.17%)
收盘价
最后更新: 2026年8月17日
3.61B USD
市值
股价为何变动
As of Aug 17, 2026, KNSA closed up 3.17% at $79.18. No new same-company headline was identified in the current news window.
公司概览
IL-1 Cardiovascular Franchise
Kiniksa Pharmaceuticals develops and commercializes therapies for diseases with strong biological rationale, with an emphasis on cardiovascular inflammation. Its portfolio is centered on blocking interleukin-1 alpha and beta signaling.
ARCALYST
ARCALYST, or rilonacept, is a weekly subcutaneous IL-1 cytokine trap approved for recurrent pericarditis and selected autoinflammatory disorders. It provides Kiniksa’s commercial foundation in pericarditis.
KPL-387
KPL-387 is an IL-1 receptor 1 monoclonal antibody being developed for recurrent pericarditis. Its target profile is a monthly self-administered injection, and a Phase 2/3 program is assessing dose selection and transition from standard therapy.
KPL-1161
KPL-1161 is an Fc-modified IL-1 receptor antibody in preclinical development. The molecule is designed for quarterly subcutaneous dosing and could extend the franchise toward substantially less frequent administration.
未来催化剂
- Phase 2 dose-focusing data for KPL-387 expected in the second half of 2026.
- Initiation of the Phase 3 pivotal KPL-387 trial expected by year-end 2026.
- Initiation of a Phase 1 trial of KPL-1161 expected by year-end 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。